Rapamycin
TL;DR
Most evidence-backed pharmacological longevity intervention. Inhibits mTORC1 → autophagic cellular cleanup + SASP suppression. ITP mouse data: +9–14% median lifespan; up to +38% in females started at ~60 human-year equivalent. Weekly low-dose protocol (5–10 mg once weekly on a rest day) delivers an autophagic pulse while sparing mTORC2, avoiding immunosuppression and insulin resistance seen at daily transplant doses. Key stacks: PCC1 (senomorphic/senolytics pair), SLU-PP-332 (mitochondrial renewal cycle), NMN NAD+ (complementary anti-aging axes), BPC-157 (repair under autophagy), GHK-Cu (SIRT1 environment optimization).
Key Facts
| Status | FDA-approved (transplant, TSC, oncology); off-label for longevity |
| Class | mTORC1 allosteric inhibitor / macrolide / geroprotective agent |
| Mechanism | FKBP12-rapamycin → FRB domain → blocks S6K1/4E-BP1 → releases ULK1 → autophagy |
| Dosing | 5–10 mg oral once weekly on a rest day; heavy training on days 5–7 (trough window) |
| Half-life | ~69 hours — enables weekly intermittent protocol; mTORC2 fully recovered by day 7 |
| Optimal monitoring | 48h post-dose (CV=0.28, r=0.72 — PMID 41046300); target Cmin <10 ng/mL |
| Hard contraindication | Transplant patients on chronic immunosuppression; calcineurin inhibitor combination (nephrotoxic); surgery within 48 h; pregnancy |
| Key risk | Aphthous ulcers (minority); mild transient hyperlipidemia; wound-healing caution 24–48 h peak window only |
| Key counterintuitive finding | Weekly dosing + exercise → lean mass increased on DEXA (PEARL RCT) — not anti-anabolic in humans when timed correctly |
| Evidence | ITP multi-site replication · AgelessRx PEARL RCT · Mannick immune restoration trials · TRIAD Dog Aging Project · Swedish AD PK study (PMID 41046300) |
mTOR Biology
mTORC1 (aging driver): Raptor subunit; activated by amino acids, insulin/growth factors, high ATP; phosphorylates S6K1 + 4E-BP1 → protein synthesis; suppresses autophagy.
mTORC2 (metabolic homeostasis): Rictor subunit; Akt Ser473 phosphorylation → insulin sensitivity, glucose homeostasis. Rictor physically masks the FRB domain → acute insensitivity to rapamycin. At high/chronic doses, newly synthesized mTOR gets bound by FKBP12-rapamycin before assembling into mTORC2 → gradual mTORC2 depletion → insulin resistance. Longevity protocol is designed to avoid this.
Lifespan Data
- ITP (Harrison et al. 2009): Rapamycin started at 600 days (~60 human years) — still worked. Median: males +9%, females +14%. From 600-day start: males +28%, females +38%. Most replicated mammalian lifespan finding in biogerontology.
- Rapamycin + Acarbose: Up to 36.6% median lifespan extension in mice — most potent pharmacological combination documented.
- Evolutionarily conserved across yeast, C. elegans, Drosophila, mice — 1.5+ billion years of conservation.
Human Clinical Evidence
- Mannick trials: Everolimus in elderly → +20% influenza vaccine response; CD4+ T-cell PD-1: −32.7%; CD8+ T-cell PD-1: −37.4%. Paradox: immunosuppressant drug improves immune function in aged.
- AgelessRx PEARL RCT (48 weeks): Weekly low-dose confirmed safe; visceral fat reduction confirmed; lean muscle mass increased on DEXA — challenges assumption of purely catabolic effect.
- Thymic rebound (2025 mice): 3-day rapamycin burst → acute involution → withdrawal → thymus grows to 1.3× baseline age-matched controls; massive DP T-cell + CD8 SP T-cell expansion. Transient suppression → functional overshoot = immune-reconstituting mechanism.
- Swedish AD pharmacokinetics (2025): 7mg once-weekly; terminal half-life 68.9 ± 13.6 h; optimal monitoring window: 48 hours post-dose (CV=0.28, strongest Cmin correlation r=0.72).
Muscle Paradox — Training Timing
mTORC1 = primary driver of muscle protein synthesis. Rapamycin sterically blocks this. But PEARL trial showed lean mass increase at weekly dosing, and 2024 RCT confirmed weekly sirolimus did NOT impair muscle strength/endurance during exercise program.
69-hour half-life creates the natural trough window:
| Day | Rapamycin Level | Training |
|---|---|---|
| Day 0 (dose day) | Cmax ~1–3 h post-ingestion | Rest day — autophagy pulse |
| Days 1–2 | ~50–75% of peak; mTORC1 inhibited | Light activity only |
| Days 3–4 | ~25–50% of peak | Moderate activity |
| Days 5, 6, 7 | ~12–25% of peak — trough | Heavy resistance training |
Protocol:
- Dose: Rest day (day 0 of 7-day cycle)
- Heavy training: Days 5, 6, 7 — mTORC2 fully recovered; mTORC1 at nadir; anabolic window fully preserved
- Blood monitoring: Draw at 48 hours post-dose (CV=0.28, lowest variability of all timepoints; r=0.72 correlation with AUC; target Cmin <10 ng/mL)
vs. XW4475: Direct mechanistic antagonism — XW4475 CRF2 → mTOR activation, rapamycin → mTOR inhibition. Simultaneous administration = futile cycle. Required protocol: Rapamycin on full rest days; XW4475 strictly peri-workout on rapamycin trough days (days 5–7) only. Do not co-administer within 24h of each other. Choose priority: longevity or muscle.
Everolimus as alternative: Everolimus (RAD001) has a shorter half-life (~30h vs ~69h for sirolimus), giving a wider anabolic training window (days 3–7 of a 7-day cycle vs days 5–7). Athletes prioritizing hypertrophy may prefer everolimus; longevity-priority users should prefer sirolimus for its longer autophagy exposure window.
Autophagy and Mitophagy
Macro-autophagy: Rapamycin peak → 24–48 h → peak autophagy. Most potent, reliable pharmacological autophagy trigger known.
Mitophagy: Selective mitochondrial clearance via mTORC1 → ULK1 →清除 damaged mitochondria. Creates cellular space + energy resource availability for new mitochondria. Urolithin A activates the same pathway via PINK1/Parkin (different entry point — direct PINK1 activation, not mTOR). These are complementary mitophagy inducers.
vs. other autophagy inducers:
- Fasting: requires 36–48 h+ to deplete glycogen
- Exercise: less reliable
- Spermidine: mild
- Rapamycin: most potent and deeply studied
Key Stacks
Rapamycin + PCC1 — Complete Senescence Protocol
Rapamycin = senomorphic (SASP suppression via mTOR → clamps SASP production without killing the cell). PCC1 = senolytic (kills senescent cells). Two-pronged: prevents toxic broadcast + permanently eliminates the cells generating it.
Rapamycin + SLU-PP-332 — The Mitochondrial Renewal Cycle
| Compound | Action | Mitochondrial Effect |
|---|---|---|
| Rapamycin | mTORC1 inhibition | Mitophagy — clears old/damaged mitochondria |
| SLU-PP-332 | ERR pan-agonism | Biogenesis — builds new mitochondria |
Sequential stack: Rapamycin clears damaged organelles → SLU-PP-332 populates cleared space with fresh, efficient mitochondria. Complete mitochondrial lifecycle management.
Rapamycin + NMN NAD+ — Complementary Anti-Aging Axes
Rapamycin: induces mitophagy, shifts NAD+/NADH to more oxidized ratio (improves SIRT1 efficiency). NMN: provides NAD+ substrate for SIRT1, builds new mitochondria via PGC-1α. Different axes: rapamycin optimizes metabolic environment, NMN provides the fuel.
Important nuance: Rapamycin does NOT reduce CD38 expression. PCC1 clears the senescent cell source of CD38. NMN is wasted on CD38 if senescent cell burden is high. Complete longevity stack: Rapamycin + PCC1 + NMN.
Rapamycin + BPC-157 — Repair Under Autophagy
BPC-157: angiogenesis (VEGFR2/NO system) + alternative FoxO3a/p-AKT/p-mTOR/p-GSK-3β pathway. Rapamycin blunts systemic repair via mTOR suppression. BPC-157 provides angiogenic and NO-driven bypass that works independently of mTOR. Preserves joint/ligament/tendon integrity during anti-anabolic longevity protocol.
Rapamycin + GHK-Cu
GHK-Cu activates SIRT1 (enzyme expression). NMN provides NAD+ substrate. Rapamycin creates oxidized NAD+/NADH environment that maximizes SIRT1 efficiency. Three together: comprehensive SIRT1 optimization (enzyme + substrate + favorable redox).
Rapamycin + Retatrutide
Retatrutide: aggressive caloric deficit → autophagy-lysosomal hyperactivation → muscle catabolism risk. Controlled rapamycin autophagic pulse during extreme fat loss protects surviving muscle architecture by clearing lipotoxic intermediates (ceramides, DAGs) and damaged mitochondria that impair insulin signaling.
Safety
Daily transplant doses: Insulin resistance, immunosuppression, hypertriglyceridemia, wound-healing impairment.
Weekly longevity doses: mTORC2 fully recovers between doses.
- Aphthous ulcers: most common, mild, self-resolving
- Mild transient hyperlipidemia (active lipolysis; monitor lipid panel)
- Infections: consistently decreased at longevity doses (Mannick + PEARL)
- Wound healing: theoretically impaired 24–48 h peak window; not clinically significant in intermittent use
- Insulin resistance: NOT seen at weekly dosing
Links
- Mitophagy — shared mechanism with Urolithin A
- PCC1 — senomorphic/senolytics pair
- SLU-PP-332 — mitochondrial renewal cycle
- NMN NAD+ — complementary anti-aging axes
- BPC-157 — repair under autophagy
- GHK-Cu — SIRT1 optimization trio
- Retatrutide — metabolic stabilizer during fat loss
- GLP-1 GIP Glucagon — metabolic overlap; Retatrutide discussed there
- Peptides MOC — peptide/compound hub index